Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Conjugation with Tris Decreases the Risk of Ketoprofen-Induced Mucosal Damage and Reduces Inflammation-Associated Methane Production in a Rat Model of Colitis

Autor: Melinda Ugocsai, Anett Bársony, Réka Anna Varga, Ámos Gajda, Noémi Vida, Norbert Lajkó, Benedek Rónaszéki, Gábor Tóth, Mihály Boros, Dániel Érces, Gabriella Varga

Publikováno v: Pharmaceutics, Vol 15, Iss 9, p 2329 (2023)

We have designed a new compound from the non-steroidal anti-inflammatory drug (NSAID) ketoprofen (Ket) and 2-amino-2-(hydroxymethyl)-1,3-propanediol (Tris) precursors, with the aim to reduce the gastrointestinal (GI) side effects of NSAID therapies.

Externí odkaz: https://doaj.org/article/a911c6fab5a14ca284b1d6694d8ae4d2

Cellular liquid biopsy provides unique chances for disease monitoring, preclinical model generation and therapy adjustment in rare salivary gland cancer patients.

Autor: Stojanović Gužvić N; Fraunhofer Institute for Toxicology and Experimental Medicine ITEM-R, Germany., Lüke F; Fraunhofer Institute for Toxicology and Experimental Medicine ITEM-R, Germany.; Department of Internal Medicine III, University Hospital Regensburg, Germany.; Bavarian Cancer Research Center (BZKF), Regensburg, Germany., Treitschke S; Fraunhofer Institute for Toxicology and Experimental Medicine ITEM-R, Germany., Coluccio A; Fraunhofer Institute for Toxicology and Experimental Medicine ITEM-R, Germany., Hoffmann M; Fraunhofer Institute for Toxicology and Experimental Medicine ITEM-R, Germany., Feliciello G; Fraunhofer Institute for Toxicology and Experimental Medicine ITEM-R, Germany., Varadarajan AR; Fraunhofer Institute for Toxicology and Experimental Medicine ITEM-R, Germany., Lu X; Fraunhofer Institute for Toxicology and Experimental Medicine ITEM-R, Germany., Weidele K; Fraunhofer Institute for Toxicology and Experimental Medicine ITEM-R, Germany., Botteron C; Fraunhofer Institute for Toxicology and Experimental Medicine ITEM-R, Germany., Materna-Reichelt S; Fraunhofer Institute for Toxicology and Experimental Medicine ITEM-R, Germany., Keil F; Bavarian Cancer Research Center (BZKF), Regensburg, Germany.; Insitute for Pathology, University of Regensburg, Germany., Evert K; Bavarian Cancer Research Center (BZKF), Regensburg, Germany.; Insitute for Pathology, University of Regensburg, Germany., Weber F; Fraunhofer Institute for Toxicology and Experimental Medicine ITEM-R, Germany.; Bavarian Cancer Research Center (BZKF), Regensburg, Germany.; Insitute for Pathology, University of Regensburg, Germany., Schamberger T; Experimental Medicine and Therapy Research, University of Regensburg, Germany., Althammer M; Experimental Medicine and Therapy Research, University of Regensburg, Germany., Grosse J; Bavarian Cancer Research Center (BZKF), Regensburg, Germany.; Department of Nuclear Medicine, University Hospital Regensburg, Germany., Hellwig D; Bavarian Cancer Research Center (BZKF), Regensburg, Germany.; Department of Nuclear Medicine, University Hospital Regensburg, Germany., Schulz C; Bavarian Cancer Research Center (BZKF), Regensburg, Germany.; Department of Internal Medicine II, University Hospital Regensburg, Germany., Seitz S; Bavarian Cancer Research Center (BZKF), Regensburg, Germany.; Department of Obstetrics and Gynecology, University Hospital Regensburg, Germany., Ugocsai P; Bavarian Cancer Research Center (BZKF), Regensburg, Germany.; Department of Obstetrics and Gynecology, University Hospital Regensburg, Germany., Schlenska-Lange A; Department of Oncology and Hematology, Hospital Barmherzige Brüder, Regensburg, Germany., Mayr R; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Germany., Kaiser U; Department of Internal Medicine III, University Hospital Regensburg, Germany.; Bavarian Cancer Research Center (BZKF), Regensburg, Germany., Dietmaier W; Insitute for Pathology, University of Regensburg, Germany., Polzer B; Fraunhofer Institute for Toxicology and Experimental Medicine ITEM-R, Germany., Warfsmann J; Fraunhofer Institute for Toxicology and Experimental Medicine ITEM-R, Germany., Honarnejad K; Fraunhofer Institute for Toxicology and Experimental Medicine ITEM-R, Germany., Pukrop T; Fraunhofer Institute for Toxicology and Experimental Medicine ITEM-R, Germany.; Department of Internal Medicine III, University Hospital Regensburg, Germany.; Bavarian Cancer Research Center (BZKF), Regensburg, Germany., Heudobler D; Department of Internal Medicine III, University Hospital Regensburg, Germany.; Bavarian Cancer Research Center (BZKF), Regensburg, Germany., Klein CA; Fraunhofer Institute for Toxicology and Experimental Medicine ITEM-R, Germany.; Bavarian Cancer Research Center (BZKF), Regensburg, Germany.; Experimental Medicine and Therapy Research, University of Regensburg, Germany., Werno C; Fraunhofer Institute for Toxicology and Experimental Medicine ITEM-R, Germany.

Publikováno v: Molecular oncology [Mol Oncol] 2024 Oct 05. Date of Electronic Publication: 2024 Oct 05.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Targeted transcript quantification in single disseminated cancer cells after whole transcriptome amplification.

Autor: Franziska C Durst, Ana Grujovic, Iris Ganser, Martin Hoffmann, Peter Ugocsai, Christoph A Klein, Zbigniew T Czyż

Publikováno v: PLoS ONE, Vol 14, Iss 8, p e0216442 (2019)

Gene expression analysis of rare or heterogeneous cell populations such as disseminated cancer cells (DCCs) requires a sensitive method allowing reliable analysis of single cells. Therefore, we developed and explored the feasibility of a quantitative

Externí odkaz: https://doaj.org/article/6e8ba3fa007749bcb8f50752c6b74437